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Abstract
Lithium (Li+) is a common treatment for bipolar mood disorder, a major psychiatric illness with a lifetime prevalence of more
than 1%. Risk of bipolar disorder is heavily influenced by genetic predisposition, but is a complex genetic trait and, to date,
genetic studies have provided little insight into its molecular origins. An alternative approach is to investigate the genetics
of Li+ sensitivity. Using the social amoeba Dictyostelium, we previously identified prolyl oligopeptidase (PO) as a modulator
of Li+ sensitivity. In a link to the clinic, PO enzyme activity is altered in bipolar disorder patients. Further studies
demonstrated that PO is a negative regulator of inositol(1,4,5)trisphosphate (IP3) synthesis, a Li
+ sensitive intracellular signal.
However, it was unclear how PO could influence either Li+ sensitivity or risk of bipolar disorder. Here we show that in both
Dictyostelium and cultured human cells PO acts via Multiple Inositol Polyphosphate Phosphatase (Mipp1) to control gene
expression. This reveals a novel, gene regulatory network that modulates inositol metabolism and Li+ sensitivity. Among its
targets is the inositol monophosphatase gene IMPA2, which has also been associated with risk of bipolar disorder in some
family studies, and our observations offer a cellular signalling pathway in which PO activity and IMPA2 gene expression
converge.
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Introduction
Bipolar mood disorder is a common psychiatric disorder, which
is treated using mood stabilizer drugs, such as lithium (Li+). There
is a strong genetic component to risk of developing bipolar
disorder, however this is a complex genetic trait and no consensus
candidate susceptibility genes have yet emerged from those
identified in individual family studies [1]. Genetics is not the only
factor affecting risk, and twin studies demonstrate the presence of
environmental inputs [2,3]. Environmental risk factors include
lifetime events and psychosocial stressors, physical illnesses and
hormonal imbalances [4]. Onset of bipolar disorder is most
frequent during late adolescence and early adulthood suggesting
contributions from developmental and physiological mechanisms.
As in the case of genetics, the biological mechanisms underlying
environmental risk are also unclear.
An alternative approach is to investigate the therapeutic
mechanisms of the mood stabilizer drugs used to treatment
bipolar disorder. Li+ is the most widely used mood stabilizer, taken
by 50% of bipolar patients. It is an effective prophylactic agent and
good anti-manic, but a weaker anti-depressant treatment [5].
Inositol monophosphatase (IMPase) and Inositol 1-polyphospha-
tase (IPP) are direct biochemical targets of Li+ [6,7], and Li+
treatment leads to reduced inositol synthesis and suppression of
inositol phosphate (IP) signalling. Consequently, it has been
proposed that the neurological processes underlying bipolar mood
disorder are susceptible to aberrant IP signalling [8]. Consistent
with this hypothesis, the structurally unrelated mood stabilizers
valproic acid (VPA) and carbamazepine also deplete inositol
[9,10], indicating a wider association between mood stabilizers
and IP signalling.
To understand why Li+ is an effective therapy, we undertook a
genetic screen for Li+ resistance in the social amoeba Dictyostelium.
This identified the serine protease prolyl oligopeptidase (PO) as a
modulator of Li+ sensitivity [11]. Interestingly, reduced PO
activity has been associated with bipolar disorder [12,13,14]. We
found that ablation of the PO gene or inhibition of PO enzyme
activity is accompanied by an increase in inositol(1,4,5)trispho-
sphate (IP3) production. This inhibitory interaction is conserved in
mammalian cells as reduced PO activity increases IP3 in
astroglioma and COS-7 kidney cell lines [10,15]. These effects
are manifest at the cellular level where PO inhibition both reverses
the effects of Li+, VPA and carbamazepine on neuronal growth
cone morphology and stimulates removal of protein aggregates via
macro-autophagy [9,10,16,17].
The mechanism by which PO controls Li+ sensitivity has not
been established. Initial Dictyostelium studies showed that PO null
mutants had unaltered phospholipase C activity but increased
activity of two inositol phosphate phosphatases. One phosphatase
activity corresponds to multiple inositol polyphosphate phospha-
tase (Mipp1), which dephosphorylates IP6 to IP3. The other is an
IP3 5-phosphatase activity that dephosphorylates IP3 further to
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I(1,4)P2 [11]. Here, we report that Mipp1 is required to mediate
the effects of PO on Li+ sensitivity. Furthermore, we show that
these effects do not arise through direct elevation of IP3 production
as previously assumed, but are due to changes in the expression of
genes involved in inositol synthesis and metabolism, including
inositol synthase (ino1), IMPase (impA1) and the Dictyostelium IP3 5-
phosphatase (Dd5P3). Finally, we show that this PO mediated
regulation of gene expression is conserved in human cells where
among its targets is IMPA2, a gene associated with risk in some
bipolar disorder patient family studies. Our observations suggest a
signalling pathway that could connect altered PO mediated
signalling to aberrant IMPA2 gene regulation.
Results
Dictyostelium PO, dpoA, reduces the effect of Li+ on
chemotaxis
Starved Dictyostelium cells aggregate by cAMP-mediated chemo-
taxis to form a multicellular mass of 100,000 cells, which develops
further into a fruiting body of spore and stalk cells [18]. We found
that PO activity is regulated throughout Dictyostelium development,
peaking during late aggregation and early multicellular stages
(Figure 1A), indicative of a regulatory function.
Li+ treatment of wild type cells has a specific effect on
chemotaxis, causing reduced cell speed and Directionality (a
measure of the linearity of the cell path) [19]. We found that
chemotaxis of dpoA mutant cells was less sensitive to Li+, with cells
exhibiting greater speed and Directionality in the presence of Li+
than wild type cells (Figure 1B; Table 1). We also noted that dpoA
mutant cells exhibited increased speed of movement in control
conditions, treatment with NaCl, suggesting that DpoA suppresses
this aspect of the chemotaxis response.
Dictyostelium PO acts via Multiple Inositol Polyphosphate
Phosphatase (Mipp1)
Previous results indicated that loss of dpoA is associated with
increased activity of multiple inositol polyphosphate phosphatase
(MIPP), an enzyme that dephosphorylates IP6, IP5 and certain IP4
species to form IP3 [11]. The Dictyostelium genome contains two
homologues of the mammalian MIPP, however only one gene,
Figure 1. Loss of dpoA reduces Li+ sensitivity. A, PO activity peaks at 8 hours of Dictyostelium development, and then declines to levels only
slightly higher than in growing cells (0 hours of development). Error Bars: mean 6 standard error of 3 independent experiments. Peak activity
corresponds to streaming and mound developmental stages. B, Cell tracks of wild type and mutant cells in 7 mM LiCl (or control of 7 mM NaCl)
during chemotaxis along a 1 nM/mm cAMP gradient (direction of arrow). D= Directionality, S = cell speed (mm/min). dpoA null mutants have a
reduced Li+ sensitivity, showing higher Directionality and speed than wild type in Li+.
doi:10.1371/journal.pone.0011151.g001
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denoted mipp1, is expressed in growing cells and during
development (data not shown). We generated null mutant cell
strains, which lack the mipp1 gene, and strains that over-expressed
Dictyostelium Mipp1. These latter strains were a useful source of
Mipp1 enzyme, which was used to show that Mipp1 rapidly
converts IP6 to IP3 (Figure 2A). mipp1 null mutants completely lack
Mipp activity and Mipp1 over-expressors greatly enhanced
activity (Figure 2B). However, total mass measurement of all
inositol phosphates (IPs) showed that loss of mipp1 had no
significant effect on the overall concentrations of IP4, IP5 and
IP6 (data not shown) suggesting that Mipp1 regulates only a small
proportion of the cellular IPs. Such robustness in the cellular
content of the higher order IPs has been observed previously and
means that small changes of the IP species involved in signalling
may be masked behind larger non-dynamic IP populations [20].
Chemotaxis of mipp1 null mutants was hypersensitive to Li+
(Figure 2C), the opposite phenotype of dpoA mutant cells. Double
dpoA:mipp1 null mutant cells possess a similar Li+ hypersensitive
phenotype to mipp1 null cells (Figure 2C), indicating that Mipp1
activity is required for PO mediated signalling. Consistent with this
we found that elevation of IP3 following PO inhibition was also
dependent on Mipp1. The IP3 concentration of wild type cells
doubled within 30 minutes of addition of the PO inhibitor Z-pro-
L-prolinal (Figure 2D). This increase was transient and IP3
returned to basal levels after 60 minutes. PO inhibitors were
unable to elevate IP3 in mipp1 null mutants (Figure 2D).
To investigate the interaction between PO and Mipp1 at the
biochemical level, we pre-incubated Mipp1 extracts with bacterially
produced recombinant DpoA protein, and then monitored Mipp1
activity. Incubation with DpoA enzyme caused an approximate two-
fold decrease in Mipp1 activity, an effect reversed by treatment with
PO inhibitor (Figure 2E). However, there was no change in the
abundance or size of the Mipp1 protein following PO treatment
(Figure 2E), arguing against direct proteolysis. Mipp1 is extracted as a
membranous particulate fraction and the most likely explanation is
that PO acts on a yet unidentified, co-purified intermediate protein or
peptide. These results however do indicate a close association
between PO activity and Mipp1 regulation.
Table 1. Chemotactic analysis of lithium sensitivity.
Relative lithium sensitivity
Strain Directionality (D) Speed (s) (mm/min) Directionality Speed
Wild type Na 0.7260.06 10.0260.42
Li 0.5960.04{{ 6.0960.45{{{
dpoA Na 0.6860.02 11.3460.571
Li 0.6760.02*** 8.2460.82* ++ ++
mipp1 Na 0.6960.02 9.6560.19
Li 0.5060.06{{{ 4.6960.58{{{ - - - -
mipp1:dpoA Na 0.7360.03 9.6260.27
Li 0.5160.04{{{ 5.4660.22{{{,$ - - -
mipp1oe Na 0.6860.03 9.0260.79
Li 0.4660.04{{{ 2.9660.12{{{ - - - - - -
ImpA1oe Na 0.7060.06 9.8060.60
Li 0.6660.05* 7.8560.43** ++ ++
ImpA1oe:Ino1oe Na 0.5160.02 18.8960.84
Li 0.4160.03 8.4860.46* - - - ++
ipkA1oe Na 0.7760.05 10.0360.80
Li 0.6860.03*** 10.0760.65*** ++ +++
ipkBoe Na 0.6960.01 10.0360.22
Li 0.7160.03*** 9.0860.95*** +++ ++
mipp1:ipkA1oe Na 0.6560.02 8.0960.59
Li 0.3660.04 4.6460.60 - - - - -
mipp1:ipkBoe Na 0.6260.11 8.7461.79
Li 0.4060.01 5.4360.54 - - - - -
Cells were treated with 7mM LiCl or NaCl (control treatment) for one hour prior to analysis. Values shown are the mean 6 standard error of data from at least three
independent experiments. Directionality is defined as the total distance moved divided by the net distance moved. Statistical analysis: two-tailed t-test.
{{{p,0.001,
{{p,0.02, compared to NaCl control treatment.
***p,0.005,
**p,0.05,
*p,0.1, compared to LiCl-treated wild-type cells.
1p,0.001, compared to NaCl treated wild type cells.
$ p,0.05, compared to LiCl treated dpoA null cells.
Relative lithium sensitivity
This is based on the difference between the numerical values for lithium treatment of wild type and mutant cells, as calculated by (value of mutant in Lithium)/(value for
WT in Lithium). For Directionality: (- - -) 60–69% of wild type; (- - -) 70–79% of wild type; (- -) 80–89% of wild type; (++) 110–119% of wild type; (+++) 120–129% of wild
type. For speed: (- - -) 25–49% of wild type; (- -) 50–74% of wild type; (-) 75–99% of wild type; (++) 125–149% of wild type; (+++) 150–174% of wild type.
doi:10.1371/journal.pone.0011151.t001
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Figure 2. Mipp1 mediates the effects of PO inhibition. A, Mipp1 enzyme prepared from Mipp1 over-expressing cells were incubated with 10
nmoles InsP6 for the indicated times and analyzed by HPLC-MDD. I(1,4)P2 was generated by contaminating IP3 5-phosphatase activity, and
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Over-expression of Mipp1 causes Li+ hypersensitivity
A simple hypothesis is that decreased PO activity controls Li+
sensitivity through Mipp1 mediated changes in IP3 abundance,
but a number of observations show this is not the case. First,
Mipp1 over-expression would be expected to increase the IP3
concentration and reduce Li+ sensitivity, however Mipp1 over-
expressing cells are strongly Li+ hypersensitive (Figure 2C).
Second, in the absence of PO inhibition, we found that neither
loss nor over-expression of Mipp1 altered the cellular concentra-
tion of IP3, despite both causing Li
+ hypersensitivity (data not
shown). This lack of correlation argues against generation of IP3 as
a direct mechanism for Li+ resistance. The same lack of reciprocity
also argues against a mechanism involving depletion of the Mipp1
substrate IP6 or its alternative substrate 2,3-bisphosphoglycerate
(2,3-BPG) [21]. I(1,3,4,5,6)P5 and I(1,4,5,6)P4/I(1,3,4,5)P4 are
intermediates in the dephosphorylation of IP6 to I(1,4,5)P3 by
Mipp1 and both have signalling properties within the cell. Mipp1
could therefore play a more complex role by regulating the
abundance of these molecules through controlling the balance of
their synthesis and degradation.
Over-expression of the IP3 kinases IpkA1 and IpkB confers
Li+ resistance
In all but one case, it was not possible to observe direct changes
in the abundance of IPs in our mutants, however the exception
was seen in Mipp1 over-expressing cells, which exhibited a large
decrease in the cellular I(1,3,4,5,6)P5 concentration, in addition to
decreased IP6 (Figure 3A). As this correlates with a strong Li
+
hypersensitive phenotype, it suggested a positive role of
I(1,3,4,5,6)P5 signalling in establishing Li
+ sensitivity. To pursue
this possibility, we over-expressed two structurally distinct IP3
kinases (IpkA1 and IpkB) each capable of generating I(1,3,4,5,6)P5
[22,23,24]. In the reverse of that seen for Mipp1 over-expression,
chemotaxis of cells over expressing either IpkA1 or IpkB was
resistant to Li+ (Figure 3B). Interestingly, we found that the Li+
resistant phenotype was lost when the IpkA1 or IpkB were over-
expressed in a mipp1 null mutant background (Figure 3B), arguing
that Mipp1 activity may be the key regulator of this signal
pathway.
DpoA acts via Mipp1-mediated gene regulation
As the yeast homologue of ipkA1, Ipk2/Arg82, controls
expression of the inositol synthase gene (ino1) [25], we investigated
potential changes in gene expression mediated by PO and Mipp1.
Expression of the Dictyostelium ino1 gene [9,26] was elevated both in
dpoA null cells and cells treated with PO inhibitor (Figure 4A,B).
Furthermore both conditions gave a 60-100% increase in
expression of the genes encoding IMPase (impA1), IPP (ippA and
ippB) and Dd5P3, a phosphatase that converts I(1,4,5)P3 to I(1,4)P2
(see Table S1). Dd5P3 is homologous to the synaptojanin-like IP3
5-phosphatase conserved from yeast to humans [27] and its
elevated expression is consistent with the elevated IP3 5-
phosphatase activity previously observed in dpoA null cells [11].
No change was seen for mipp1, dpoA or ipkA1 genes (Figure 4B).
demonstrates that the product of Mipp1 is I(1,4,5)P3. B, Mipp1 activity measured as the rate of IP3 formation in extracts from wild type, mipp1 null
mutant and Mipp1overexpressingcells. C, Cell tracks of wild type and mipp1 mutant cells in 7 mM LiCl (or control of 7 mM NaCl) during chemotaxis.
mipp, mipp:dpoA and Mipp1 over-expressing mutants (Mipp1oe) are Li+ hypersensitive compared to wild type. D = Directionality, S = cell speed (mm/
min). D, Vegetative wild type and mipp1 null cells were treated with either 1.2 mM Z-pro-L-prolinal or an equal volume of DMSO carrier as a control.
Samples were then removed at the times indicated and IP3 concentration measured. Values plotted as mean 6 standard error of 4 independent
experiments. * P,0.05, paired T-test. E, Mipp1 protein extracts were incubated with recombinant DpoA with or without the PO inhibitor Z-pro-L-
prolinal. Mipp1 activity is measured by the production of IP3 from IP6. Values plotted as mean 6 standard error of 3 independent experiments.
** P,0.01, paired T-test. Samples of Mipp1 protein are shown on Western (underneath).
doi:10.1371/journal.pone.0011151.g002
Figure 3. Elevated expression of Mipp1 and IP3 kinases alter lithium sensitivity. A, Comparison of the I(1,3,4,5,6)P5 and IP6 concentration
of wild type, dpoA null; mipp1 null and Mipp1 over-expressing cells. Values plotted (means 6 standard error of 3 independent experiments) as
percentage of the total IP content relative to wild type (*P,0.05, ** P,0.01 T-test). B, Cell tracks of wild type and mipp1 null mutant cells over-
expressing IpkA1 and IpkB during chemotaxis in 7 mM LiCl. D = Directionality, S = cell speed (mm/min). Over-expression of IpkA1 and IpkB in wild
type cells confers Li+ resistance, whereas Li+ hypersensitivity is maintained after over-expression in a mipp1 null mutant.
doi:10.1371/journal.pone.0011151.g003
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Changes in gene expression were dependent on Mipp1, as mipp1
null mutant cells treated with the PO inhibitor exhibited no
change in the expression of ino1 or impA1 (Figure 4C). Further-
more, in the absence of PO inhibitor, Mipp1 over-expression
caused a 50% decrease in expression of impA1, although ino1 was
unaffected (Figure 4C). Finally, IpkA1 and IpkB over-expression
elevated ino1 and impA1 gene expression in the absence of PO
inhibition (Figure 4D), again supporting a signalling role of the
higher order IPs.
Previously, we demonstrated that elevated expression of impA1
in Dictyostelium cells reverses Li+ inhibition of chemotaxis [19]. This
is consistent with the uncompetitive inhibition mechanism of Li+
on IMPase, which unlike other modes of inhibition is only reversed
by increased enzyme concentration. This mechanism alone offers
an explanation for how PO inhibition could confer Li+ resistance,
however our observations on gene expression suggest a more
extensive effect of PO on expression of multiple inositol synthetic
genes. This could combine to enhance Li+ resistance. We
investigated cells with elevated expression of both impA1 and
ino1 and found that they appeared to be Li+ resistant.
Quantification showed that in terms of cell speed, impA1:ino1
over-expressing cells were Li+ resistant in comparison to wild type
cells. However, we also observed that these cells exhibited higher
cell speed compared to wild type cells in the Na+ control treatment
Figure 4. PO regulates gene expression. A, Expression of ino1 in wild type, dpoA null cells and wild type cells following overnight treatment with
1.2 mM Z-pro-L-prolinal (PO inhibitor), measured by Northern analysis. rnlA expression was used as a loading control. The graph shows the expression
of ino1 quantified on a phosphoimager (Biorad) and normalised to rnlA relative to wild type or DMSO carrier treated controls (mean 6 standard error
of 3 independent experiments). B, The expression of genes involved in inositol metabolism (Table S1). Gene expression in wild type cells following
overnight treatment with Z-pro-L-prolinal or the equivalent amount of DMSO carrier, and dpoA null mutant cells was measured by qRT-PCR, and
normalised to rnlA expression levels. Values plotted are relative to the carrier control cells (mean 6 standard error of 3 independent experiments).
* P,0.05, ** P,0.01, *** P,0.005, T-Test. C, mipp1 is required for the regulation of gene expression by PO. Expression of ino1 and impA1 in wild type
and mipp1 null cells following overnight treatment with Z-pro-L-prolinal or the equivalent amount of DMSO carrier, was measured by qRT-PCR, and
normalised to rnlA expression levels. Values plotted are relative to the carrier control wild type cells (mean6 standard error of at least 3 independent
experiments). There is a significant difference in gene expression between wild type and mipp1 null mutant following PO inhibition (** P,0.01, T-
Test). D, Expression levels of ino1, impA1 and mipp1 in wild type, mipp1 null mutant and cells over-expressing Mipp1, IpkA1 or IpkB. Expression was
calculated relative to either wild type, or wild type cells transformed with the empty expression vector as appropriate. All samples were normalised to
rnlA as a loading control and the values plotted are the mean 6 standard error of 3 independent experiments (*P,0.05, ** P,0.01 T-test). ND = not
determined.
doi:10.1371/journal.pone.0011151.g004
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(Figure 5 A,B). In contrast, Directionality was reduced in both Na+
control and Li+ treated cells, effectively making the cells more
sensitive than wild type with regard to this parameter. These
observations demonstrate that whilst mis-regulation of multiple
genes may enhance overall Li+ resistance, there is likely to be more
complexity to the regulation, either involving more genes than ino1
and impA1 or perhaps a finer balance in levels of expression.
PO and Mipp1 modulate gene expression in HEK293 cells
These results show that PO and Mipp1 control expression of the
Dictyostelium inositol synthetic genes (Figure 6A). A key question is
whether a similar modulatory pathway exists in human cells. We
therefore examined the effects of PO inhibition on HEK293 cells.
PO inhibition caused a strong elevation of expression of the
human IMPase genes, IMPA1 and IMPA2 (Figure 6B). siRNA to
knockdown human Mipp1 expression again demonstrated that
this increase was dependent on Mipp1. Interestingly, basal IMPA1
expression was reduced by mipp1 siRNA (Figure 6B), suggesting
that in these human cells, IMPA1 expression may be more
dependent on Mipp1 function than other co-regulated genes. PO
inhibitors also lead to a smaller Mipp1-dependent elevation in
expression of the human inositol synthase gene ISYNA1.
Discussion
These results indicate that PO and Mipp1 are key components
of a gene regulatory network that controls expression of the
Dictyostelium inositol synthetic genes (Figure 6A). We suggest that
this may act in Dictyostelium during aggregation stage of
development to modulate chemotaxis. It has previously been
observed that Dictyostelium change their chemotactic response
during aggregation in order to accommodate changes in cAMP
signalling as cells approach multicellularity [28]. Little is known
about the mechanisms that mediate these changes, however we
observed elevated PO activity during these later stage of
aggregation, and note that DpoA appears to act as a suppressor
of cell speed during chemotaxis, suggesting that the PO/Mipp1
signal pathway could be involved with these developmental
changes.
The rapid elevation of IP3 in response to PO inhibition, suggests
a series of direct interactions within this signalling pathway, and
consistent with this we see no change in mipp1 mRNA following
PO inhibition. Furthermore, we show that incubation with
recombinant PO decreases Mipp1 activity in cell extracts. This
in vitro effect does not proceed via proteolysis of Mipp1, and
therefore is likely to involve an unidentified intermediate peptide
or protein.
In addition, we show that although I(1,4,5)P3 is the Mipp1
product, it is not the modulator of Li+ sensitivity. Instead, we show
that this occurs via altered expression of the genes that encode the
myo-inositol synthetic and metabolic genes. This fits biochemical
observations as Li+ is an uncompetitive inhibitor of the IMPase
and IPP [6,29] and hence targets the enzyme-substrate complex.
Uncompetitive inhibitors can only be overcome by increasing the
amount of enzyme, and we have previously shown that increased
expression of ImpA1 reduces Li+ sensitivity of Dictyostelium cells
undergoing chemotaxis [19]. We also previously found that in the
absence of Li+, elevated ImpA1 enhances signalling via PIP3, an
important mediator of the chemotaxis in Dictyostelium and
signalling in other cells. We now show that a combined increase
in expression of impA1 and ino1genes, as occurs in the dpoA null
mutant, enhances the degree of Li+ resistance with regard to cell
speed and also alters the chemotactic response in the absence of
Li+. A combined up-regulation of gene expression would be
expected to have significant effects on PIP3 signalling.
The exact nature of the link between Mipp1 and gene
expression requires further study, however genetic evidence
implicates signalling via changes in the metabolism of the higher
order inositol phosphates, I(1,3,4,5,6)P5 and I(1,4,5,6,)P4 [30].
I(1,3,4,5,6)P5 is a good candidate for a signalling and has
Figure 5. Increased ino1 and impA1 gene expression confers Li+ resistance. A, Cell tracks of wild type cells over-expressing ImpA1 alone or
both ImpA1and ino1 undergoing chemotaxis in 7 mM NaCl or LiCl. D = Directionality, S = cell speed (mm/min). B, Cells of wild type cells over-
expressing ImpA1 alone or both ImpA1and ino1were developed in the presence of 10 mM LiCl. Images are taken after 24 hours, bar = 5 mm.
doi:10.1371/journal.pone.0011151.g005
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previously been observed in the control of ino1 and pho gene
expression in yeast [25]. In mammals, recent results indicate the
I(1,3,4,5,6)P5 rapidly accumulates following Wnt3A stimulation
[31].
To investigate the effects of PO inhibition in animal cells, we
examined PO inhibition and siRNA knock down of Mipp1in
HEK293 cells. As found in Dictyostelium, expression of ino1
(ISYNA1), IMPA1 and the IMPase paralogue IMPA2 are
increased in a Mipp1 dependent manner following treatment
with PO inhibitors. Interestingly, basal IMPA1 expression was
reduced by Mipp1 siRNA and no subsequent elevation of
expression was seen with PO inhibition. This suggests that in
human cells, expression of IMPA1 may have a greater
requirement for Mipp1 activity than other genes. We note that
although the same dependency is not seen in Dictyostelium, we did
observe a differential inhibitory effect on impA1and ino1 following
Mipp1 over-expression (Figure 4D). It is currently unclear how
these differences in expression arise between genes, however we
suggest that they reside in subtle differences in their promoter
structure.
How might PO mediated signalling be relevant to bipolar mood
disorder? First, altered PO activity has been observed in bipolar
disorder patients. In manic phase patients prior to treatment,
plasma PO activity is elevated, but then reduced to below that of
control patients following mood stabilizer treatment [13]. In a
follow up study, PO activity was shown to be below that of control
groups in euthymic patients [14]. Both sets of measurements were
made using plasma, however PO is a cytosolic enzyme and plasma
levels of activity are 1,000-fold less than intracellular activity [14].
The relationship between intracellular activity and patients has not
yet been explored.
The potential causes of altered PO activity are unknown, but as
single nucleotide polymorphism (SNP) analysis has failed to find a
genetically significant association of PO with risk of bipolar
disorder [32], it may arise from environmental or physiological
effects. High doses of the cytokine IFN-a in patients undergoing
immunotherapy are reported to decrease serum PO activity and
be associated with some symptoms of depression [33], and mood
disorders in general have previously been associated with an
activation of the inflammatory response. A recent report found
bipolar disorder patients have altered expression of a subset of
genes that are associated with the pro-inflammatory response,
including those involved in cytokine signalling and chemotaxis
[34]. Furthermore twin studies showed that these changes arise
through a common environmental factor, not a shared genetic
component [34]. Altered PO activity may therefore reflect an
environmental or physiological component for risk of bipolar
disorder.
Second, genetic studies suggest that the presence of a specific set
of SNPs within the IMPA2 gene promoter associates with elevated
risk for bipolar disorder in some family studies [35,36,37]. Some of
these SNPs have been shown to elevate promoter activity when
coupled to marker genes and may also associate with elevated
expression in post-mortem brain samples, although these studies
may be confounded by differences in brain pH [37]. Global
differences in brain IMPase activity have not been substantiated
[38,39], although differences could be missed by sampling
different populations, or if changes only occur in a small subset
of cells or brain regions.
Third, we have identified a novel signal pathway, where PO acts
to suppress gene expression of the inositol synthetic and metabolic
genes. It seems significant that PO suppresses IMPase gene
expression, which is a Li+ target. In Dictyostelium, loss of PO leads to
reduced Li+ sensitivity. This would seem the opposite case to that
seen in patients, where Li+ treatment suppresses a clinical state.
However, the difference may be that Li+ treatment of Dictyostelium
cells leads to a quantifiable difference in cell behaviour, whereas
no behavioural difference has been observed in human non-
patient controls. Our Dictyostelium experiments can be viewed from
an alternative perspective, where our mutant Dictyostelium cells
possess aberrant signalling and in some cases exhibit altered
chemotaxis behaviour. Li+ treatment suppresses this aberrant
signalling behaviour so that it now falls into the behavioural
parameters measured in wild type cells prior to Li+ treatment. For
example in the case of both the dpoA null mutant and ino1:impa1
over-expressors we observed differences in chemotactic behaviour
that were reversed by Li+ treatment. Similarly we have previously
observed elevated PIP3 signalling in wild type cells over-expressing
Figure 6. PO regulates expression of human IMPA1, IMPA2 and ISYNA1 genes. A, A diagram to illustrate the gene regulatory network
through which PO activity regulates expression of the IMPA1, IMPA2 and ISYNA1 genes. The gene regulatory network is separate from ligand-
stimulated regulation of IP3 signalling via phospholipase C (PLC), but interacts via changes in gene expression or interchange of soluble IP3. * marks
genes and enzyme activities associated with bipolar mood disorder. B, HEK293 cells were treated with either mipp1 specific or non-targetting siRNA
for 24 hours with or without 130 mM Z-pro-L-prolinal (PO inhibitor). Gene expression was quantified by qRT-PCR using expression of B2M as a
reference. Expression of IMPA1, IMPA2 and ISYNA1 genes was quantified as percentage relative change compared to control (DMSO carrier treated,
non-targeted siRNA samples). * p,0.05, ** p,0.02, *** p,0.001.
doi:10.1371/journal.pone.0011151.g006
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impa1 in the absence of Li+, which is suppressed by Li+ treatment
[19].
We therefore envisage that treatment of patients may fit a
general model, where elevated signalling activity is suppressed by
mood stabilizer treatment. We propose that altered transcriptional
control of inositol synthetic and metabolic genes, particularly
IMPA2, could contribute to elevated risk of bipolar disorder. This
risk could be heightened through changes in PO activity. In the
simplest scenario, a genetic predisposition for elevated IMPA2
expression could be enhanced though an environmentally
mediated decrease in PO activity leading to overactive cell
signalling. Long-term Li+ treatment would in turn suppress
elevated cell signalling to compensate for elevated gene expression.
Although this will be difficult to directly demonstrate in patient
studies, further genetic analysis and development of model systems
will be useful to probe the clinical relevance of PO-mediated
signalling.
Materials and Methods
Analysis of Cell movement
All Dictyostelium mutants and over-expressing strains were
generated in the AX2 parental background (Materials and
Methods S1) and grown using standard methods [40]. Cells were
shaken at 106 cells/ml for 5 hours in KK2 with 6-minute pulses of
100 nM cAMP every 6 minutes. Lithium was added for the final
hour of pulsing. Cells were placed in 1 mM gradient of cAMP[41]
and images collected every 10 seconds on a DIC inverted
microscope. Data was analysed using DIAS 3.4.1 analytical
software (Soll Technologies Inc; [42]). Data sets were analysed for
statistical significance using a Mann-Whitney U-test, and based on
200–300 cells per experiment.
Biochemical analysis. PO activity was measured as
described by Williams et al (1999) [11]. For MIPP activity, cell
extracts were prepared as described by Van Dijken et al (1995)
[43] and incubated with an equal volume of TEE [20 mM
triethanolamine pH 6.5, 5.9 mM EGTA, 0.5 mM EDTA]
supplemented with 20 mM CaCl2, 50 mM LiCl and 200 mM
IP6. Production of IP3 was measured by an isotope dilution assay
(Perkin Elmer). For HPLC-MDD analysis, IP were prepared from
109 cells and resuspended in 400 ml 0.1 M NaCl, 15 mM NaF,
0.5 mM EDTA pH 6.0, and quantified by hplc analysis using
Tricorn Mini Q 4.6/50 PE columns (GE healthcare) with solutions
A: (21 mM YCl3) and B (0.8 M HCl, 25 mM YCl3 (Merck). Post-
column detection used (2.13 M triethanolamine, 500 mM 4-(29-
Pyridylazo)-Resorcinol (PAR) (Merck), pH 9.75) and absorbance
[44] at 520 nm [45,46].
Analysis of gene expression
Northern blotting was done using standard techniques. For
qRT-PCR analysis of Dictyostelium samples, total RNA was
extracted from growing cells and used as template to generate
cDNA using random primers (Roche 1st Strand synthesis kit).
qRT-PCR was then performed using a SYBR green mastermix kit
(Abgene), with 10 ng cDNA template and PCR primers described
in Materials and Methods S1. All samples were run in triplicate,
with at least three biological replicates. Expression differences were
calculated using the 22DDcT method [47] normalised to rnlA in
Dictyostelium and B2M in HEK 293 cells.
Supporting Information
Materials and Methods S1 Construction of mutant strains and
plasmids; qRT-PCR primers.
Found at: doi:10.1371/journal.pone.0011151.s001 (0.05 MB
DOC)
Table S1 Summary of the genes identified and manipulated in
this study. mRNA copy number was determined by quantitative
RT-PCR, by using a calibration curve generated from plasmid
clones of each gene, assuming that 1% of total RNA is mRNA.
The activity of genes marked * is predicted by homology with
characterised enzymes from other species. [Williams RS, Eames
M, Ryves WJ, Viggars J, Harwood AJ (1999) EMBO J 18: 2734–
2745; Fischbach A, Adelt S, Muller A, Vogel G (2006) Biochem J.
397:509–518.; King JS, Teo R, Ryves J, Reddy JV, Peters O,
Harwood, AJ. (2009) Dis Model Mech 2: 306–312.; Loovers HM,
Veenstra K, Snippe H, Pesesse X, Erneux C, et al. (2003) J Biol
Chem 278: 5652–5658].
Found at: doi:10.1371/journal.pone.0011151.s002 (0.08 MB
DOC)
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